Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Inhibition of Dipeptidyl Peptidase (DPP)-4 With Sitagliptin for the Prevention of Acute Graft Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation

NCT02683525 is registered in ClinicalTrials.gov with Sherif S. Farag as lead sponsor.

NCT NCT02683525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02683525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Inhibition of Dipeptidyl Peptidase (DPP)-4 With Sitagliptin for the Prevention of Acute Graft Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Lead sponsor
Sherif S. Farag
Phase
Phase 2
Overall status
Completed
Start date
February 3, 2016
Completion date
October 1, 2019
Enrollment
37 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

graft vs host disease, hematopoietic stem cell transplantation